Imfinzi improved EFS in resectable lung cancer
9 March 2023 07:00 GMT Imfinzi significantly improved event-free survival in AEGEAN Phase III trial for patients with resectable non-small cell lung cancer Results showed that Imfinzi-based treatment before and after surgery significantly increased the time patients live without recurrence or progression events Positive high-level results from a planned interim analysis of the AEGEAN Phase III, placebo- controlled trial showed that treatment with AstraZeneca's Imfinzi (durvalumab) in combination with neoadjuvant chemotherapy before surgery and as adjuvant monotherapy after